Genetic variants in cell cycle control pathway confer susceptibility to lung cancer

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5974-5981

  Wang, Wei ^a   Spitz, Margaret R ^a   Yang, Hushan ^a   Lu, Charles ^a   Stewart, David J ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P27; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE REGULATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INTRON; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING HABIT; UNTRANSLATED REGION;

ADULT; CASE-CONTROL STUDIES; CELL CYCLE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; SMOKING; VARIATION (GENETICS);

EID: 35348879174     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0113     Document Type: Article

References (47)

1. Keith RL, Miller YE. Lung cancer: genetics of risk and advances in chemoprevention. Curr Opin Pulm Med 2005;11:265-71.
2. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;23:9408-21.
3. 1-S phase of the cell cycle and alterations in the RB pathway in human lung cancer. Expert Rev Anticancer Ther 2006;6:515-30.
4. Dobashi Y. Cell cycle regulation and its aberrations in human lung carcinoma. Pathol Int 2005;55:95-105.
5. Caputi M, Russo G, Esposito V, et al. Role of cell-cycle regulators in lung cancer. J Cell Physiol 2005;205:319-27.
6. 2/M arrest after DNA damage. J Biol Chem 2001;276:42971-7.
7. 1-phase arrest: TP53-dependent and TP53-independent roles. Radiat Res 2003;159:72-85.
8. Vincenzi B, Schiavon G, Silletta M, et al. Cell cycle alterations and lung cancer. Histol Histopathol 2006;21:423-35.
9. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004;204:101-9.
10. Abdulkader I, Sanchez L, Cameselle-Teijeiro J, et al. Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study. Oncol Rep 2005;14:1527-31.
11. Malusecka E, Zborek A, Krzyzowska-Gruca S. Changes in expression of pRb, p16 and cyclin D1 in non-small cell lung cancer: an immunohistochemical study. Folia Histochem Cytobiol 1999;37:19-24.
12. Gu J, Spitz MR, Zhao H, et al. Roles of tumor suppressor and telomere maintenance genes in cancer and aging - an epidemiological study. Carcinogenesis 2005;26:1741-7.
13. Clurman BE, Porter P. New insights into the tumor suppression function of P27(kip1). Proc Natl Acad Sci U S A 1998;95:15158-60.
14. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005;65:3980-5.
15. Hartwell JL. Plants used against cancer. A survey. Lloydia 1970;33:288-392.
16. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis 2000;21:379-85.
17. Popanda O, Schattenberg T, Phong CT, et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 2004;25:2433-41.
18. Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 2006;78:464-79.
19. Cheng TC, Chen ST, Huang CS, et al. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer 2005;113:345-53.
20. Kimura MT, Mori T, Conroy J, et al. Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk. Cancer Res 2005;65:3548-54.
21. Le Marchand L, Seifried A, Lum-Jones A, et al. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 2003;290:2843-8.
22. Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002;94:681-90.
23. Gu J, Zhao H, Dinney CP, et al. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res 2005;11:1408-15.
24. Gu J, Gong Y, Huang M, et al. Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 2007;28:350-5.
25. Park JK, Lee HJ, Kim JW, et al. Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. Schizophr Res 2004;67:71-4.
26. Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 2004;25:1568-73.
27. Biros E, Kalina I, Kohut A, et al. Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. Lung Cancer 2001;31:157-62.
28. Jiang J, Wang J, Suzuki S, et al. Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population. J Cancer Res Clin Oncol 2006;132:193-9.
29. Zhang J, Li Y, Wang R, et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer 2003;105:281-4.
30. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003;63:7056-61.
31. Millard SS, Vidal A, Markus M, et al. A U-rich element in the 5′ untranslated region is necessary for the translation of p27 mRNA. Mol Cell Biol 2000;20:5947-59.
32. Miskimins WK, Wang G, Hawkinson M, et al. Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol Cell Biol 2001;21:4960-7.
33. Cox DG, Hankinson SE, Hunter DJ. Polymorphisms of the AURKA (STK15/Aurora kinase) gene and breast cancer risk (United States). Cancer Causes Control 2006;17:81-3.
34. Miao X, Sun T, Wang Y, et al. Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res 2004;64:2680-3.
35. Egan KM, Newcomb PA, Ambrosone CB, et al. STK15 polymorphism and breast cancer risk in a population-based study. Carcinogenesis 2004;25:2149-53.
36. Ewart-Toland A, Briassouli P, de Koning JP, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 2003;34:403-12.
37. Mohrenweiser HW, Wilson DM III, Jones IM. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 2003;526:93-125.
38. Millikan RC, Hummer A, Begg C, et al. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis 2006;27:610-8.
39. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773-85.
40. Yang P, Schwartz AG, McAllister AE, et al. Genetic analysis of families with nonsmoking lung cancer pro-bands. Genet Epidemiol 1997;14:181-97.
41. Brownson RC, Alavanja MC, Caporaso N, et al. Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol Rev 1998;20:218-36.
42. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93.
43. Kim TM, Yim SH, Lee JS, et al. Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 2005;11:8235-42.
44. Wang Y, Zhang Z, Lubet R, et al. Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf. Oncogene 2005;24:3042-9.
45. Campling BG, El-Deiry WS. Clinical implication of p53 mutation in lung cancer. Mol Biotechnol 2003;24:141-56.
46. Quinones LA, Irarrazabal CE, Rojas CR, et al. Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J Androl 2006;8:349-55.
47. Schabath MB, Wu X, Wei Q, et al. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:158-61.